Earlier studies have observed decreased cancer risk in G6PD deficient patients, in particular for cancers of endodermal origin (colorectal, gastric and liver), but these findings were not replicated in other studies, notably for hematologic malignancies. The gene discussed is G6PD; the disease is hematologic disorder.